My Vaccine Report Download !!HOT!!

As of October 2023, there are three COVID-19 vaccines recommended for use in the United States to protect against COVID-19 disease. These vaccines are monitored by VAERS and several other vaccine safety monitoring systems as part of the most intensive vaccine safety monitoring effort in U.S. history. This continuous, robust safety monitoring helps keep COVID-19 vaccines safe and helps ensure the benefits of vaccination continue to outweigh any risks.

Healthcare providers are required to report certain adverse events following COVID-19 vaccination to VAERS. Learn about COVID-19 vaccine Emergency Use Authorization (EUA) reporting requirements for healthcare providers.

My Vaccine Report Download

Download 🔥 https://bytlly.com/2y7YaL 🔥

VAERS is part of the larger post-licensure vaccine safety monitoring system in the United States. After vaccines are licensed or authorized for use by FDA, they are continually monitored for safety by multiple, complementary systems. These systems also conduct safety studies in populations that are larger and more diverse than those typically included in vaccine clinical trials.

The number of VAERS reports submitted varies each year. In 2019, VAERS received over 48,000 reports. About 85-90% of the reports described mild side effects such as fever, arm soreness, or mild irritability. The remaining reports are classified as serious, which means that the reported adverse event resulted in permanent disability, hospitalization, prolongation of an existing hospitalization, life-threatening illness, congenital deformity/birth defect or death. While these events can happen after vaccination, they are rarely caused by the vaccine.

In some cases, multiple reports are submitted for the same adverse event. For example, the person who experienced the adverse even and their healthcare provider could submit a report for the same adverse event. VAERS scientists review the reports, identify any duplicates, and attach them to the original submission. This review process ensures the same adverse event is not counted more than once, even in cases where there are multiple reports on the same adverse event. Only the primary reports are shown in the public data system, not additional or follow-up reports for the same event.

This specific limitation has caused confusion about the publicly available data, specifically regarding the number of reported deaths. In the past there have been instances where people misinterpreted reports of death following vaccination as death caused by the vaccines; that is a mistake.

VAERS accepts all reports of adverse events following vaccination without judging whether the vaccine caused the adverse health event. Some reports to VAERS might represent true vaccine reactions, and others might be coincidental adverse health events not related to vaccination at all.

The Vaccine Adverse Event Reporting System (VAERS) is a national early warning system to detect possible safety problems in vaccines used in the United States. VAERS accepts and analyzes reports of adverse events (AEs) after a person has received a vaccination. Anyone can report an adverse event to VAERS. Healthcare professionals are required to report certain adverse events and vaccine manufacturers are required to report all adverse events that come to their attention.

Online reporting is strongly encouraged. Please report clinically important adverse events that occur after vaccination of adults and children, even if you are not sure whether the vaccine caused the adverse event.

*Beyfortus (nirsevimab) is not a vaccine. It is a monoclonal antibody given by injection and used in newborns, infants, and young children to protect them from respiratory syncytial virus (RSV). It may be given at the same time that vaccinations are given.

The vaccination provider must report all serious* adverse events following administration of JYNNEOS or ACAM2000 vaccine and vaccine administration errors to the Vaccine Adverse Event Reporting System (VAERS) by submitting online at

Submit a VAERS report online. The report must be completed online and submitted in one sitting and cannot be saved and returned to at a later time. Your information will be erased if you are inactive for 20 minutes; you will receive a warning after 15 minutes.

Download the Writable PDF Form to a computer. Complete the VAERS report offline if you do not have time to complete it all at once. Return to this page to upload the completed Writable PDF form by clicking here.

Each VAERS report is assigned a VAERS identification number. This number can be used to provide additional information about the report to VAERS, if necessary. VAERS will send the identification number to the reporting individual in a confirmation letter (electronically or by mail, depending on communications preferences listed on the original report).

The VAERS program follows up on reports classified as serious by attempting to obtain medical records to better understand the event. These requests for medical records are made directly to health institutions or public health authorities that create and maintain medical records. The medical records are added to the permanent record under the VAERS ID, compliant with privacy standards.

Information identifying the person who received the vaccine and the person who filed the report is not made available to the public. You or your health care provider may be contacted for further information after your report is received.

VAERS is primarily concerned with monitoring adverse health events and we encourage reporting of clinically significant adverse health events following vaccination. Using clinical judgment, healthcare professionals can decide whether or not to report a medical error at their own discretion. For example, a healthcare professional may elect to report vaccination errors that do not have an associated adverse health event, especially if they think the vaccination error may pose a safety risk (e.g., administering a live vaccine to an immunocompromised patient) or that the error would be preventable with public health action or education.

Also report any additional select adverse events and/or any revised safety reporting requirements per FDA's conditions of authorized use of vaccine(s) throughout the duration of any COVID-19 Vaccine being authorized under an Emergency Use Authorization (EUA).

The NYC Health Department's Citywide Immunization Registry (CIR) collects New Yorkers' vaccine records to help ensure that people receive life-saving immunizations, to monitor vaccination rates and to protect public health.

Immunization records are for people born in NYC after 1995 and records for adults who consent to have their vaccinations reported by their health care provider. Providers in NYC must report all COVID-19 and flu vaccinations to the Health Department.

If your record is not found in the CIR (or it contains no immunizations), you should contact your health care provider and ask them to report your immunization history and future immunizations to the CIR. The provider can call the Provider Access Line at 866-692-3641 for more information.

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.

Results: After the first vaccination, antibody responses were higher with higher dose (day 29 enzyme-linked immunosorbent assay anti-S-2P antibody geometric mean titer [GMT], 40,227 in the 25-g group, 109,209 in the 100-g group, and 213,526 in the 250-g group). After the second vaccination, the titers increased (day 57 GMT, 299,751, 782,719, and 1,192,154, respectively). After the second vaccination, serum-neutralizing activity was detected by two methods in all participants evaluated, with values generally similar to those in the upper half of the distribution of a panel of control convalescent serum specimens. Solicited adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Systemic adverse events were more common after the second vaccination, particularly with the highest dose, and three participants (21%) in the 250-g dose group reported one or more severe adverse events.

Conclusions: The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461).

As of January 3, 2024, Georgia DPH will be transitioning from the COVID-19 vaccine interactive dashboard to a new weekly report. The weekly report will provide details on COVID-19 vaccination data available to DPH following the end of the Public Health Emergency.

"Receiving the COVID-19 vaccine allowed me to affect change and turn faith into action. I believe the vaccine helps save lives, stabilize our economy, and ensure a safer future for generations to come. I encourage all to take action and be vaccinated."

As previously announced, the Pennsylvania Immunization Registry is transitioning to a new Immunization Information System named Pennsylvania Immunization Electronic Registry System (PIERS) with a go-live date of January 17, 2024. Virtual training sessions via Teams will be held twice daily beginning November 14, 2023. The first session will be held from 8:00 am - 10:30 am and the afternoon session will be held from 1:00 pm - 3:30 pm. In-person trainings will begin December 4, 2023, with one in-person training offered in each of the six Community Health Districts. Office staff, medical assistants, nurses, physicians, and pharmacists responsible for documenting immunization information and managing vaccine inventory and orders should take this class. We encourage all users to take a live class, whether virtual or in-person. If you are unable to attend one of these live trainings, we will also have a self-paced training recording available on TRAIN PA in the near future. 006ab0faaa